natgillin/translations-raw huggingface dataset:
A method for producing a coated particle, comprising a first step of dry-coating a nuclear particle with hydroxyalkyl cellulose and a binder thereby adhesion-coating the nuclear particle with a coating layer; wherein the binder is at least one selected from the group consisting of polyalkylene glycol, polyalkylene glycol higher fatty acid ester, higher fatty acid, higher alcohol, higher alcohol ester and natural wax; and wherein the hydroxyalkyl cellulose has a volume average particle size of from 0.1 to 20 µm 
Postupak proizvodnje obložene čestice, naznačen time što se sastoji u prvom koraku suhog oblaganja osnovne čestice hidroksialkilcelulozom i vezivom, čime se osnovnu česticu adhezijski oblaže slojem obloge; gdje je vezivo u najmanju ruku ono koje se bira iz skupine koju čine polialkilen-glikol, ester polialkilen-glikol s višom masnom kiselinom, viša masna kiselina, viši alkohol, ester višeg alkohola i prirodni vosak; i gdje hidroksialkilceluloza ima prosječnu volumnu veličinu čestica od 0,1 do 20 um.
Plasma is isolated by centrifugation and frozen prior to analysis. 
Plazma je izdvojena ccntrifugiranjem, to zamrznuta prije analize.
Y is -CH2-. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein: Ring A is an unsaturated fused heterobicyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group; 
a je atom halogena, C1-6 alkilna skupina ili C1-6 alkoksi skupina; a i R3a su atomi vodika; a je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom, halogen-C1-6 alkilnom skupinom, C1-6 alkoksi skupinom, halogen-C1-6 alkoksi skupinom, te mono- ili di-C1-6 alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom ili C1-6 alkoksi skupinom; i Y je -CH2-.
TEA were charged to the flask. 
TEA bilo je stavljeno u tikvicu.
gelling agent, neutralizing agent, 
- < sredstvo za neutraliziranje,
A corresponding dosage form is known to the person skilled in the art, for example under the name oral osmotic therapeutic system (OROS), as are suitable materials and methods for the production thereof, inter alia from U.S. Pat. 
Stručnjaku je među ostalim iz US 4,612,008, US 4,765,989 i US 4,783,337 poznat odgovarajući oblik davanja primjerice pod oznakom oralni osmotski terapeutski sistem (OROS), isto tako kao i prikladni materijali i postupci njihove proizvodnje.
Table 1: Known endoglucanase of the GH7 class 
Datum podnošenja europske prijave patenta:
In the first step of the process according to the invention a polyolefin powder is compacted in an isobaric press. 
Postupak prema zahtjevu 1 gdje je izobarična preša kontinuirana dvo-remenska preša.
The process of clause 59, wherein the reaction mixture in step (c) comprises an organic solvent selected from the group consisting of methylcyclohexane, cyclohexane, heptane, hexane, toluene, and mixtures thereof. 
Postupak prema patentnom zahtjevu 38, pri čemu reakcijska smjesa u koraku (c) sadrži organsko otapalo u kojem sporedni proizvod M-R> ima nisku otopljivost, izabran iz grupe koju čine metilcikloheksan, cikloheksan, heptan, heksan, toluen i njihove smjese.
The method of any one of E1-E16, E29, and E30, wherein the multiple sclerosis is secondary progressive multiple sclerosis. 
Postupak, uporaba, terapijsko sredstvo, ili agonist L-21 prema bilo kojem od prethodnih zahtjeva, naznačen time da multipla skleroza je sekundarna progresivna multipla skleroza.
A particular feature of the present invention is that the martensitic transformation of the zirconia particles can be provoked by a trigger mechanism. 
Određeno svojstvo ovog izuma je da martenzitska transformacija čestica cirkonijeva oksida započne mehanizmom za poticanje.
heating the waste in a chamber to an elevated temperature to effect pyrolysis of the waste; 
- < zagrijavanje otpada u komori na visoku temperaturu kako bi se provela piroliza otpada;
The method of claim 9, wherein the antibody or antigen binding fragment thereof, or the immunoconjugate is in a pharmaceutical composition, wherein the immunoconjugate in the pharmaceutical composition comprises an average of 3 to 4 (c) per antibody or antigen binding fragment thereof. 
Farmaceutska kompozicija koja sadrži imunokonjugat iz bilo kojeg od patentnih zahtjeva 7-15, gdje imunokonjugat ima prosjek od oko 3 do oko 4 (C) po (A) ili prosjek od oko 3.5 (C) po (A).
The method of claim 20, wherein the discharging includes actuating at least one valve of the plurality of valves prior to actuating another valve, and the actuating includes turning on pressurized air in at least one valve for a period of time before turning it off. 
Postupak prema zahtjevu 13, naznačen time da ispuštanje sadrži aktiviranje barem jednog ventila od mnoštva ventila prije aktiviranja drugog ventila, te gdje aktiviranje sadrži uključivanje stlačenog zraka u barem jednom ventilu kroz vremenski period prije njegovog isključivanja.
P1-Har-Gly-Asp(O-P2)-Trp-Pro-ACys-NH2 wherein ACys-NH2 is an activated cysteinamide; attaching a mercaptopropionic acid residue to the 2-7 eptifibatide fragment through a disulfide linkage between the mercaptopropionic acid residue and the ACys-NH2 residue of the 2-7 eptifibatide fragment, thereby forming a compound of formula I: wherein 
P,-Har-Gly-Asp(O-P2)-Trp-Pro-ACys-NH> u čemu je ACys-NH> aktivirani cisteinamid; vezivanje ostatka merkaptopropionske kiseline na fragment 2-7 eptifibatida preko disulfidne veze između ostatka merkaptopropionske kiseline i ACys-NH, ostatka fragmenta 2-7 eptifibatida, da na taj način nastane spoj formule I:
Compound of formula (III) may be prepared according to the method defined in scheme 2. 
Spoj formule (III) može se dobiti postupkom definiranim u Shemi 2.
Floor panel according to any of the preceding claims, characterized in that the locking element (12) is provided in the distal side of the male part (8). 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je tijelo za zaključavanje (14) izvedeno kao kruto tijelo.
The method according to claim 5, wherein the inhibitor of the endocannabinoid-degrading enzyme is selected from the group consisting of JZL184 and URB597. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se inhibitor enzima koji razgrađuje endokanabinoide bira iz skupine koju čine IZL184 i URB597.
The organic phase was washed with NH4Cl (sat.), dried over MgSO4, filtered and evaporated. 
Organska faza se ispere s NH,CI (zas.), osuši preko MgSO,, filtrira i upari.
A preferred formulation is one obtained from 0.9% sodium chloride or other suitable infusion vehicle, 250 µg of ET-743 with 250 mg of mannitol, 34 mg of monopotassium phosphate, and phosphoric acid to adjust the pH. 
Poželjni oblik je onaj dobiven iz 0.9% natrijklorida ili drugog pogodnog infuzijskog nosača, 250 ug ET-743 s 250 mg manitola, 34 mg monokalij fosfata i fosforne kiseline za podešavanje pH vrijednosti.
the HCDR1 comprises the amino acid sequence of SEQ ID NO: 6. The antibody of claim 1, wherein: the VL comprises the amino acid sequence of SEQ ID NOs: 62 or 63; and the VH comprises the amino acid sequence of SEQ ID NOs: 64, 65, 66, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 149, 150 or 151, or having 1, 2 or 3 amino acid substitutions at the VH linear amino acid residue positions 11, 56 or 106; or 
-HCDRI sadrži sekvence aminokiselina SEK ID BR:6. Protutijelo sukladno patentnom zahtjevu 2, naznačeno time, da: a. = VL sadrži sekvence aminokiselina od SEK ID BR-a: 62 ili 63; 1 VH sadrži sekvence aminokiselina od SEK ID BR-a: 64, 65, 66, 101, 102, 149, 150 ili 151, ili koje ima 1, 2 ili 3 supstituciju aminokiselina na položajima linearnih ostataka aminokiselina VH 11, 56 ili 106; ili b.
The compounds of the present invention are directed to peroxisome proliferator activated receptor (PPAR) agonists. 
Spojevi prema ovom izumu odnose se na agoniste receptora aktiviranog peroksisomskim proliferatorom (PPAR).
The soft chewable veterinary composition of claim 26, wherein the macrocyclic lactone is eprinomectin, ivermectin, selamectin, abamectin, dimadectin, doramectin, emamectin, latidectin, lepimectin, milbemectin, milbemycin D, milbemycin A3, milbemycin A4, milbemycin oxime, moxidectin, or nemadectin, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 26, naznačen time, da makrociklički lakton je eprinomektin, ivermektin, selamektin, abamektin, dimadektin, doramektin, emamektin, latidektin, lepimektin, milbemektin, milbemicin D, milbemicin A3, milbemicin Ay, milbemicin oksim, moksidektin ili nemadektin, ili njihova kombinacija.
q is an integer of 0 to 1, and n is an integer of 1 to 4. The protein-active agent conjugate of any one of items 9 to 11, wherein the active agent is attached to a group containing a second functional group (FG2) that can react with the FG1, wherein the FG2 is selected from the group consisting of: acetylene, hydroxylamine, azide, aldehyde, hydrazine, ketone, and amine. 
R, je vodik, Cig alkil, Cig alkil aril ili Cig alkil heteroaril, rip su svaki neovisno cijeli broj od 0 do 6, qje cijeli broj od O do 1,injecijeli broj od 1 do 4, pri čemu je aktivno sredstvo vezano na skupinu koja sadržava drugu funkcionalnu skupinu (FG2) koja može reagirati s FGI1, pri čemu je FG2 odabran iz skupine koju čine: acetilen, hidroksilamin, azid, aldehid, hidrazin, keton, i pri čemu je aktivno sredstvo vezano na skupinu koja sadržava FG2 preko ili [ZCH;CH20 (CH2CH;0),,CH2CH2Z]-, pri čemu,
A process for the synthesis of a compound according to claim 1, in which the process comprises a process for the synthesis of an acid salt of N-methylcyclopentylamine, the process comprising the reductive amination of cyclopentanone in the presence of an acid salt of methylamine. 
Postupak sinteze spoja u skladu s patentnim zahtjevom 1, naznačen time što se postupak sastoji u postupku sinteze kisele soli N-metilciklopentilamina, gdje postupak uključuje reduktivno aminiranje ciklopentanona u prisutnosti kisele soli metilamina.
selecting one or more of the events based on a profile index associated with a respective event and on at least one attribute derived from the respective event, the profile index relating at least to a link on which the vehicle was travelling at a point during the respective event; determining (4) a driver profile (24) from the selected events; and characterising (9) the driving behaviour of the driver on the basis of the driver profile. 
Odabira jednog ili više događaja temeljenih na indeksiranim profilima povezanim sa navedenim događajima 1 na najmanje jednom atributu deriviranom iz navedenog događaja, indexirani profil povezan barem prema poveznici kojom je se vozilo kretalo u trenutku navedenog događaja; utvrđivanje (4) profila vozača (24) iz odabranog događaja; i određivanje (9) ponašanja u vožnji vozača temeljem vozačevog profila. 2.
Bake at 165 °C for 14 minutes, until golden and slightly browned around the edges. 
Peći 14 minuta pri 165% C, dok kolač ne poprimi zlatnožutu, a rubovi svijetlosmeđu boju.
A, B, C, and D are reactive moieties capable of reacting with the free thiol groups each containing one or more charges, wherein each of the A, B, C, and D reactive moieties independently contain a moiety selected from the group consisting of a vinyl sulfone, an acrylate group, a methacrylate group, a styrene group, an acryl amide group, a methacryl amide group, a maleate group, a fumarate group, and an itaconate group; (R)n is a linker that contains two or more charges, wherein the charges are opposite to the charges on the reactive moieties, wherein R is a monomer, n = 1-10, and wherein (R)n is not a polymer, and the sum of the charges is zero, and 
A, B, €, 1 D su reaktivni dijelovi koji su u stanju reagirati sa slobodnim tiolnim skupinama od kojih svaki sadrži jedan ili više naboja, gdje svaki od reaktivnih dijelova A, B, C, i D neovisno sadrži skupinu odabranu iz skupine koju čine vinil sulfon, akrilatna skupina, metakrilatna skupina, stirenska skupina, akrilamidna skupina, metakrilamidna skupina, maleatna skupina, fumaratna skupina, i itakonska skupina; (R), je vezivna skupina koja sadrži dva ili više naboja, gdje su naboji suprotni nabojima reaktivnih dijelova, pri čemu je R monomer, n = 1-10, i gdje (R), nije polimer, i zbroj naboja je nula, i gdje su reaktivni dijelovi ionski vezani za vezujuću skupinu; pri čemu je svaki p, q, r, i s neovisno cijeli broj od O do 25, i pri čemu je zbroj p + q +1 + s jednak 1li veći od 2, u učinkovitoj količini da se kovalentno veže za slobodne tiolne skupine.
Preparation of Preservative Solution. 
Priprava otopine konzervansa
Composition of biotin and at least another drug against Hepatic encephalopathy for simultaneous, separate or sequential (spread out over time) use in the treatment of amyotrophic lateral sclerosis. 
Pripravak biotina i barem još jednog lijeka protiv jetrene encefalopatije za istodobnu, odvojenu ili uzastopnu (raspoređenu tijekom vremena) primjenu u liječenju jetrene encefalopatije tipa C, naznačen time što dnevna količina biotina koja se daje pacijentu iznosi najmanje 200 mg.
transmitting the modulated signal frame, 
Odašiljanje moduliranog okvira signala
Biotin for use thereof in the treatment of multiple sclerosis, wherein said treatment with biotin has a duration of at least 3 months. 
Biotin naznačen time da je za uporabu za liječenje multiple skleroze.
On such conditions, Meldonium absorbs 10% water (as to mass increase) during 24 hours. 
Pod takovim uvjetima, meldonij za 24 sata apsorbira 10% vode (kao porast mase).
The composition according to any one of claims 1 to 7, wherein the photoactivator further comprises a mixture chosen from saffron red powder, annatto extract and brown algae extract. 
Kompozicija za primjenu prema patentnim zahtjevima 1 do 7, gdje je navedeno vrijeme tretmana oko 60 sekundi do oko 5 minuta.
A process according to claim 1 wherein the hydrogen content of the hydrocarbon/hydrogen mixture is in the range 1 to 30% by volume. 
Postupak prema zahtjevu 1 ili zahtjevu 2 gdje je sadržaj vodika u smjesi ugljikovodik/vodik u rasponu 1 do 30% volumena.
The pharmaceutical composition according to Embodiment 6, wherein the buffer is present in an amount sufficient to adjust the pH of the pharmaceutical composition to a pH in the range of from pH 3.5 to pH 6.5. The pharmaceutical composition according to Embodiment 6, wherein the buffer is present in an amount sufficient to adjust the pH of the composition to a pH in the range of from pH 4.5 to pH 5.5. 
Farmaceutski sastav prema zahtjevu 5, pri čemu se pufer nalazi u količini koja je dovoljna da se podesi pH farmaceutskog sastava do pH u opsegu od pH 3.5 do pH 6.5; ili pri čemu se pufer nalazi u količini koja je dovoljna da se podesi pH sastava do pH u opsegu od pH 4.5 do pH 5.5.
This example, namely, (1-furan-2-ylmethyl-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-acetic acid is made by the same process as that described for Example 61, using the appropriate furan methyl ester. 
Ovaj primjer, naime (1-furan-2-ilmetil-2-metil-1H-pirolo[2,3-b]piridin-3-il)-octena kiselina proizvedena je istim postupkom kao što je opisano za primjer 61, upotrebom odgovarajućeg furan metil estera,
1 and 2, number 1 indicates as a whole a rotary mixing member specially designed for assembly in an axially rotating manner inside the bowl 2 of a known blender, in which bowl 2 is substantially cylindrical, with the radius of curvature Ro of the inner cylindrical surface preferably, though not necessarily, ranging between 10 and 20 centimetres. 
Referirajući se na Slike 1 12, broj 1 označava rotacioni članak za miješanje kao cjelinu posebno dizajniran za montiranje na aksijalno okretljivi način unutar zdjele 2 poznate miješalice, u čemu je zdjela 2 u biti cilindrična s radijusom zakrivljenosti Ry unutarnje cilindrične plohe pogodno, ali ne nužno, u rasponu između 10 i 20 centimetara.
anchoring the vessel (1) at an anchoring location (4) proximate the suction location, via the at least one lower suction pipe section only, and 
- sidrenja plovila (1) na mjestu sidrenja (4), blizu mjesta usisavanja, uz pomoć samo najmanje jednog donjeg dijela usisne cijevi, i
after the child removes the first flexible wrapping the first play object is revealed to the child, and the child can open the generally spherical shell to reveal the surprise toy contained therein. 
prvo udubljenje sadrži prvi od igraćih objekata (30); i prvi omotač (20) pokriva prvo udubljenje, tako da kada korisnik ukloni prvi omotač (20), otkrije se prvi igraći objekt (30).
The compound or therapeutically acceptable salt of claim 1, wherein the compound has formula (V) 
Spoj ili njegova terapijski prihvatljiva sol, naznačen time, da je spoj odabran iz skupine koja se sastoji od:
A method for preventing or treating tuberculosis reactivation in a subject, the method comprising the step of administering to a mammal already infected with Mycobacterium tuberculosis an immunologically effective amount of a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein or an immunogenic fragment thereof from a Mycobacterium species of the tuberculosis complex, wherein the expressed Mtb72f fusion protein induces an immune response against M. tuberculosis, thereby preventing tuberculosis reactivation. 
Farmaceutski pripravak, naznačen time što sadrži nukleinsku kiselinu koja kodira fuzijski protein Mtb72f, ili njegov imunogeni fragment, iz Mycobacterium vrste tuberculosis kompleksa, namijenjenu upotrebi u sprječavanju ili odgađanju reaktivacije kod sisavca koji ima latentnu infekciju bakterijom Mycobacterium tuberculosis. Farmaceutski pripravak u skladu s patentnim zahtjevom 18, naznačen time što je nukleinska kiselina iz SEQ ID NO:1.
A segment 26 of the lower edge of the cup wall 22 is folded inwardly and upwardly to engage an annular, downwardly extending skirt section 28 of the cup bottom 24. 
Segment 26 donjeg ruba stijenke 29 čaše je preklopljen prema unutra i prema gore, da bi se dobila prstenasta, rubna sekcija 28 dna 24 Caše, koja se pruža prema dolje.
A composition for protecting an animal from an invertebrate parasitic pest comprising a parasiticidally effective amount of a compound of any of Claims 1 to 9 and at least one carrier. 
Kompozicija za zaštitu životinje od štetnog parazitskog beskičmenjaka koja sadrži paraziticidno efikasnu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 9 i najmanje jedan nosač.
No: Number of the molecule 
Broj objave europskog patenta:
The present investigators have found that submucosal injections at positions 10, 2, and 6 o'clock of the cross-sectional axis of the urethra to be particularly suitable for the treatment of urinary incontinence. 
Dosadašnji istraživači su našli da su naročito prikladna submukozna injektiranja na položajima koji odgovaraju položaju male kazaljke na satru u 10 sati, 2 sata i 6 sati u poprečnom presjeku na os mokraćne cijevi kod liječenja urinarne inkontinencije.
A composition comprising at least one active ingredient selected from an a2 adrenergic receptor agonist, a pharmaceutically acceptable salt thereof and a combination thereof for use in the therapeutic reduction of skin sagging, creasing and/or wrinkling, wherein the a2 adrenergic receptor agonist is selected from the group consisting of brimonidine, tetrahydrozaline, oxymetazoline, and xylometazoline, and wherein said composition is to be topically administered to the sagging, creasing, and/or wrinkling skin of a person in need of treatment in an amount effective for amelioration of skin sagging, creasing and/or wrinkling. 
HR P20140397 T1 PATENTNI ZAHTJEVI Spoj koji sadrži najmanje jedan aktivni sastojak odabran među agonistima o, adrenergičkih receptora, neku njegovu farmaceutski prihvatljivu sol i neku kombinaciju istoga za primjenu u svrhu terapeutskog smanjivanja opuštanja i boranja kože, naznačen time da je taj agonist a2 adrenergičkih receptora odabran iz skupine koju sačinjavaju brimonidin, tetrahidrozolin, oksimetazolin i ksilometazolin i time da se spomenuti spoj nanosi lokalno na opuštenu, namreškanu i/ili naboranu kožu osobe kojoj je potreban tretman, u količini koja je djelotvorna za ublažavanje opuštanja, mreškanja i/ili boranja kože.
GB-1,126,426 discloses a surgical sock whose leg portion comprises alternate courses of a first stretch yam (100/4 denier) and intervening courses of a second elastic yam (70 denier Lycra core wrapped with two ends of 70 denier Fluflon), the first yarn being knit in every wale of the alternate courses throughout the leg portion, the second yarn being elastic and being knit in alternate wales and floated across intervening wales throughout the major portion of the leg portion. 
GB-1,126,426 opisuje kirurške kratke čarape, čiji nožni dio obuhvaća naizmjenične redove prvog rastezljivog konca (100/4 deniera) i između njih redove drugog elastičnog konca (jezgra od Lycre od 70 deniera omotana s dva kraja Fluflona od 70 deniera), pri čemu se prvi konac plete na svakom kraju naizmjeničnih redova uzduž nožnog dijela, a drugi konac je elastičan i on se plete na svakom drugom kraju i nosi se preko posrednih rubova uzduž glavnog dijela nožnog dijela.
In another embodiment, the invention provides a compound of formula I-G 
8. - Spoj prema patentnom zahtjevu 1, pri čemu je spoj formule I-G
is a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a cyclo-lower alkyl group optionally substituted by a halogen atom, or is an aryl group, an aralkyl group or a heteroaromatic group optionally having a substituent selected from a group consisting of a halogen atom, a cyano group, an amino group and a lower alkyl group; 
je niža alkilna skupina, niža alkenil skupina, niža alkinil skupina ili ciklo-niža alkilna skupina po izboru supstituirana halogen atomom, ili je aril skupina, aralkil skupina ili heteroaromatska skupina koja po izboru ima supstituent odabran iz grupe koju čine halogen atom, cijano skupina, amino skupina i niža alkilna skupina;
After cooling to room temp, the benzene layer was decanted from the dark oil in the bottom of the flask and was concentrated. 
Poslije hlađenja na sobnoj temperaturi, sloj benzola je odliven iz tamnog ulja na dnu posude i koncentriran.
“Substituted phenyl” means phenyl substituted with up to 3 substituents selected from halo, —CN, —NO2, —OH, optionally halo-substituted C1-3 alkyl (e.g. 
Â« Supstituirani ari Â« znači aril supstituiran sa supstituentom sa do 3 supstituenta odabrana od halo, -CN, -NO», -OH, po izboru halo-supstituirani Cia alkil (na pr.
and R8 are independently hydrogen, linear or branched, substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R7 and R8 taken together form an optionally substituted 3-8 membered carbocyclyl or heterocyclyl; and R10 are independently hydrogen, optionally substituted C4-C8 cyclyl or optionally substituted C3-C8 heterocyclyl, with the proviso that at least one of R9 and R10 is not hydrogen; 
Spoj prema zahtjevu 1 ili 2, pri čemu su R9 i R10neovisno vodik, opcijski supstituirani C1-C10alkil, opcijski supstituirani C4-C6ciklil ili opciono supstituisani C4-C6heterociklil; ili R9 i R10zajedno sa ugljenikom za koji su vezani obrazuju 3-, 4-, 5-, ili 6-člani ciklil.
Floor panel according to any of the preceding claims, characterized in that said locking element (12) is provided at said male part (8). 
Podni panel prema patentnom zahtjevu 1 do 6, naznačen time što je element za blokiranje (12) napravljen koekstruzijom.